[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3453387T3 - Doseringsplan til en s1p-receptoragonist - Google Patents

Doseringsplan til en s1p-receptoragonist Download PDF

Info

Publication number
DK3453387T3
DK3453387T3 DK18201062.9T DK18201062T DK3453387T3 DK 3453387 T3 DK3453387 T3 DK 3453387T3 DK 18201062 T DK18201062 T DK 18201062T DK 3453387 T3 DK3453387 T3 DK 3453387T3
Authority
DK
Denmark
Prior art keywords
receptor agonist
dosage plan
dosage
plan
agonist
Prior art date
Application number
DK18201062.9T
Other languages
English (en)
Inventor
Robert Schmouder
Thomas Dumortier
Olivier David
Michael Looby
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3453387(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3453387T3 publication Critical patent/DK3453387T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18201062.9T 2008-12-22 2009-12-21 Doseringsplan til en s1p-receptoragonist DK3453387T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13967208P 2008-12-22 2008-12-22
US21853009P 2009-06-19 2009-06-19
US24671509P 2009-09-29 2009-09-29
EP16182876.9A EP3120844A1 (en) 2008-12-22 2009-12-21 Dosage regimen for a s1p receptor agonist

Publications (1)

Publication Number Publication Date
DK3453387T3 true DK3453387T3 (da) 2020-08-10

Family

ID=41667217

Family Applications (3)

Application Number Title Priority Date Filing Date
DK18201062.9T DK3453387T3 (da) 2008-12-22 2009-12-21 Doseringsplan til en s1p-receptoragonist
DK18179301.9T DK3409274T3 (da) 2008-12-22 2009-12-21 Doseringsskema for en s1p-receptoragonist
DK09797234.3T DK2379067T3 (da) 2008-12-22 2009-12-21 Doseringsregimen for fingolimod til behandling af multipel sklerose

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK18179301.9T DK3409274T3 (da) 2008-12-22 2009-12-21 Doseringsskema for en s1p-receptoragonist
DK09797234.3T DK2379067T3 (da) 2008-12-22 2009-12-21 Doseringsregimen for fingolimod til behandling af multipel sklerose

Country Status (41)

Country Link
US (11) US20100160259A1 (da)
EP (7) EP3120844A1 (da)
JP (7) JP2012513401A (da)
KR (1) KR101347919B1 (da)
CN (1) CN102264359A (da)
AR (1) AR074826A1 (da)
AU (1) AU2009330176C9 (da)
BR (1) BRPI0923500A2 (da)
CA (1) CA2747802C (da)
CL (2) CL2011001529A1 (da)
CO (1) CO6390117A2 (da)
CR (1) CR20110274A (da)
CU (1) CU20110136A7 (da)
CY (4) CY1116990T1 (da)
DK (3) DK3453387T3 (da)
EA (1) EA201100978A1 (da)
EC (1) ECSP11011222A (da)
ES (3) ES2760607T3 (da)
FR (1) FR20C1060I1 (da)
HN (1) HN2011001759A (da)
HR (3) HRP20151190T1 (da)
HU (4) HUE048717T4 (da)
IL (3) IL213170A0 (da)
LT (3) LT3409274T (da)
LU (1) LUC00183I2 (da)
MA (1) MA32981B1 (da)
ME (2) ME03802B (da)
MX (2) MX2011006623A (da)
NO (1) NO2020038I1 (da)
NZ (1) NZ593065A (da)
PE (1) PE20120337A1 (da)
PL (3) PL2379067T3 (da)
PT (3) PT3453387T (da)
RS (2) RS59857B1 (da)
SG (1) SG171404A1 (da)
SI (3) SI3409274T1 (da)
TN (1) TN2011000272A1 (da)
TW (1) TW201028143A (da)
UY (1) UY32352A (da)
WO (1) WO2010075239A1 (da)
ZA (2) ZA201103863B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785484B2 (en) 2008-03-17 2014-07-22 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
MX2011006623A (es) 2008-12-22 2011-07-12 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p.
CN102548579A (zh) 2009-09-29 2012-07-04 诺瓦提斯公司 S1p受体调节剂的给药方案
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
EA201201515A1 (ru) * 2010-05-06 2013-08-30 Новартис Аг Схема приема производных диарилсульфидов
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
EA026144B9 (ru) 2011-01-07 2021-10-26 Новартис Аг Твердофазная фармацевтическая композиция, содержащая гемифумаратную соль 1-{4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил}азетидин-3-карбоновой кислоты, и таблетка, ее содержащая
WO2012112933A1 (en) 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
CN104540800B (zh) 2012-08-17 2017-05-10 埃科特莱茵药品有限公司 制备(2z,5z)‑5‑(3‑氯‑4‑((r)‑2,3‑二羟基丙氧基)苯亚甲基)‑2‑(丙亚氨基)‑3‑(邻甲苯基)噻唑烷‑4‑酮的方法及在该方法中所用的中间产物
AU2014225534A1 (en) * 2013-03-06 2015-09-24 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
KR20160141841A (ko) * 2014-04-10 2016-12-09 노파르티스 아게 Ｓ１ｐ 조절제 즉시 방출 투여 요법
EP4056179A1 (en) 2014-12-11 2022-09-14 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
NZ771435A (en) * 2015-01-06 2024-08-30 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
JP2023501217A (ja) 2019-10-31 2023-01-18 イドーシア ファーマシューティカルズ リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2579602B2 (ja) 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
ATE412408T1 (de) 2002-05-16 2008-11-15 Novartis Pharma Gmbh Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP2359821A1 (en) * 2004-11-29 2011-08-24 Novartis AG Dosage regimen of an s1p receptor agonist
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP1850689A4 (en) * 2005-02-10 2013-05-22 G I View Ltd TECHNIQUES FOR DISPLACING A GASTROINTESTINAL TOOL EQUIPPED WITH A GUIDING ELEMENT
DK2952177T3 (da) * 2007-10-12 2021-04-26 Novartis Ag Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
US8785484B2 (en) * 2008-03-17 2014-07-22 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
WO2009155475A1 (en) * 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
BRPI0923213A2 (pt) * 2008-12-22 2016-01-26 Novaris Ag regime de dosagem de um agonista do receptor para s1p.
MX2011006623A (es) 2008-12-22 2011-07-12 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p.

Also Published As

Publication number Publication date
LT3409274T (lt) 2020-02-10
US20220142949A1 (en) 2022-05-12
DK2379067T3 (da) 2015-12-07
US20200330407A1 (en) 2020-10-22
US20140148415A1 (en) 2014-05-29
ME03594B (me) 2020-07-20
DK3409274T3 (da) 2019-12-16
US20190091180A1 (en) 2019-03-28
CA2747802C (en) 2021-02-09
JP7329965B2 (ja) 2023-08-21
BRPI0923500A2 (pt) 2018-05-29
IL278914A (en) 2021-01-31
MA32981B1 (fr) 2012-01-02
ES2552823T3 (es) 2015-12-02
RS59857B1 (sr) 2020-02-28
ECSP11011222A (es) 2011-08-31
US20140066657A1 (en) 2014-03-06
CY2020036I2 (el) 2021-06-25
CR20110274A (es) 2011-07-19
CO6390117A2 (es) 2012-02-29
SI3409274T1 (sl) 2020-03-31
PL2379067T3 (pl) 2016-02-29
HUE048717T2 (hu) 2020-08-28
CN102264359A (zh) 2011-11-30
EP3409274A1 (en) 2018-12-05
EA201100978A1 (ru) 2012-01-30
PE20120337A1 (es) 2012-04-24
EP4098256A1 (en) 2022-12-07
ZA201205942B (en) 2013-03-27
JP2017141238A (ja) 2017-08-17
SI2379067T1 (sl) 2016-01-29
WO2010075239A1 (en) 2010-07-01
PT3409274T (pt) 2019-12-17
FR20C1060I1 (fr) 2020-12-25
JP2019167360A (ja) 2019-10-03
MX2011006623A (es) 2011-07-12
PT2379067E (pt) 2015-12-23
ES2810823T3 (es) 2021-03-09
JP2012513401A (ja) 2012-06-14
HRP20201167T1 (hr) 2020-12-11
JP2024129030A (ja) 2024-09-26
HRP20151190T1 (hr) 2016-01-01
EP3677260A1 (en) 2020-07-08
NO2020038I1 (no) 2020-11-18
EP3120844A1 (en) 2017-01-25
AU2009330176C9 (en) 2017-01-05
KR101347919B1 (ko) 2014-01-07
AU2009330176C1 (en) 2016-12-08
US20160081949A1 (en) 2016-03-24
JP2014144970A (ja) 2014-08-14
PL3409274T3 (pl) 2020-06-01
RS60666B1 (sr) 2020-09-30
SG171404A1 (en) 2011-07-28
IL274756A (en) 2020-07-30
HUE048717T4 (hu) 2022-02-28
US20170189353A1 (en) 2017-07-06
LT3453387T (lt) 2020-08-25
PL3453387T3 (pl) 2020-11-02
AU2009330176A1 (en) 2011-07-07
US20160263061A1 (en) 2016-09-15
UY32352A (es) 2010-07-30
ZA201103863B (en) 2012-10-31
EP3409274B1 (en) 2019-11-20
CL2013001558A1 (es) 2013-10-25
LUC00183I2 (da) 2024-07-01
EP2379067A1 (en) 2011-10-26
ME03802B (me) 2021-04-20
KR20110096175A (ko) 2011-08-29
EP2379067B1 (en) 2015-09-02
JP2022103194A (ja) 2022-07-07
SI3453387T1 (sl) 2020-10-30
JP2016135752A (ja) 2016-07-28
MX2021010759A (es) 2022-07-19
US20100160259A1 (en) 2010-06-24
NZ593065A (en) 2012-11-30
AU2009330176B2 (en) 2014-03-06
PT3453387T (pt) 2020-08-11
HUE026869T2 (en) 2016-08-29
TW201028143A (en) 2010-08-01
EP2907511A1 (en) 2015-08-19
CA2747802A1 (en) 2010-07-01
CY1122812T1 (el) 2021-05-05
US20110257133A1 (en) 2011-10-20
IL213170A0 (en) 2011-07-31
CY2020036I1 (el) 2021-03-12
LTPA2020005I1 (lt) 2020-12-10
HUE052048T2 (hu) 2021-04-28
CY1123255T1 (el) 2021-10-29
US20180289638A1 (en) 2018-10-11
CL2011001529A1 (es) 2012-02-24
HRP20192175T1 (hr) 2020-03-20
TN2011000272A1 (en) 2012-12-17
AR074826A1 (es) 2011-02-16
CU20110136A7 (es) 2012-01-31
EP3453387B1 (en) 2020-06-03
CY1116990T1 (el) 2017-04-05
HN2011001759A (es) 2013-11-26
ES2760607T3 (es) 2020-05-14
HUS2000046I1 (hu) 2020-12-28
EP3453387A1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
LTC2379069I2 (lt) S1p receptoriaus agonisto dozavimas
CY2020036I1 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
DK2274032T3 (da) Anordning til medicinindgivelse
DK2355867T3 (da) Anordning til medikamentafgivelse
DK2381986T3 (da) Lægemiddeladministrationsanordning
BR112013002096A2 (pt) compostos de agonistas de receptor glp-1 possuindo regiões estabilizadas
BRPI0915781A2 (pt) oxazolopiridimas como agonista do receptor edg-1
DK2364185T3 (da) Disubstituerede phthalazin-hedgehog-pathway-antagonister
IL231945A0 (en) Funding dosing regimen for s1p receptor modulator or agonist
TH0901005765A (th) ข้อกำหนดขนาดใช้สำหรับตัวทำการของตัวรับ S1P (S1P Receptor Agonist)
TH108550B (th) เมลาโนคอร์ทิน รีเซพเตอร์ อะโกนิสท์
TH110389B (th) กลูโคคอร์ติคอยด์รีเซพเตอร์อะโกนิสท์ใหม่